



Institute Report No. 293

Mutagenic Potential of DIGL-RP Solid Propellant in the Ames Salmonella/Mammalian Microsome Mutagenicity Test

Steven K. Sano, BA, SGT and Don W. Korte, Jr., PhD, MAJ, MSC

GENETIC TOXICOLOGY BRANCH DIVISION OF TOXICOLOGY



September 1988

Toxicology Series: 150

LETTERMAN ARMY INSTITUTE OF RESEARCH PRESIDIO OF SAN FRANCISCO, CALIFORNIA 94129

the public release and sales in a constant to a unitable.

e 8 12 19 077

Mutagenic Potential of DIGL-RP Solid Propellant in the Ames Salmonella/Mammalian Microsome Mutagenicity Test (Toxicology Series 150)--Sano and Korte

This document has been approved for public release and sale; its distribution is unlimited.

Destroy this report when it is no longer needed. Do not return to the originator.

Citation of trade names in this report does not constitute an official endorsement or approval of the use of such items.

> This material has been reviewed by Letterman Army Institute of Research and there is no objection to its presentation and/or publication. The opinions or assertions contained herein are the private views of the author(s) and are not to be construed as official or as reflecting the views of the Department of the Army or the Department of Defense. (AR 360-5)

COL, MC

Commanding

28 Sqt 88 (datë)

UNCLASSIFIED SECURITY CLASSIFICATION OF THIS PAGE					
	r DOCUMENTATIO	N PAGE			Form Approved OMB No. 0704-0188
1a. REPORT SECURITY CLASSIFICATION unclassified		16. RESTRICTIVE	MARKINGS		L
2a. SECURITY CLASSIFICATION AUTHORITY		3 DISTRIBUTION	I / AVAILABILITY	OF REPORT	<u> </u>
2b. DECLASSIFICATION/DOWNGRADING SCHE	DULE	Approved i		release	; distribution
4. PERFORMING ORGANIZATION REPORT NUI	MBER(S)	5. MONITORING	ORGANIZATION	REPORT NU	MBER(S)
Institute Report No. 293					
6a. NAME OF PERFORMING ORGANIZATION Genetic Toxicology Branch Division of Toxicology	6b. OFFICE SYMBOL (If applicable) SGRD-ULE-T	7a. NAME OF M US Army Bi Laborato	omedical R	GANIZATION esearch	and Development
6c. ADDRESS (City, State, and ZIP Code) Letterman Army Institute of R Presidio of San Francisco, CA		7b. ADDRESS(Ci Ft. Detr Frederic			
8a. NAME OF FUNDING/SPONSORING ORGANIZATION US Army Medical Research & Development Command		9. PROCUREMEN	T INSTRUMENT	IDENTIFICAT	ION NUMBER
8c. ADDRESS (City, State, and ZIP Code)		10. SOURCE OF	FUNDING NUME	BERS	
Ft. Detrick Frederick, MD 21701-5012		PROGRAM ELEMENT NO.	PROJECT NO.	TASK NO.	WORK UNIT ACCESSION NO.
		62720A	835	AB	
12. PERSONAL AUTHOR(S) Steven K. Sano and Don W. 13a. TYPE OF REPORT 13b. TIM	Korte, Jr.	Mutagenici 14. Date of Repo	ty Test	· · · · · ·	PAGE COUNT
	Toxi	cology Serie	es 150		
17. COSATI CODES FIELD GROUP SUB-GROUP	18. SUBJECT TERMS (Mutagenicity Genetic Toxico Ames Test	DIG	L-RP		by block number)
The mutagenic potential of Salmonella/Mammalian Microsof TA102 were exposed to doses was not mutagenic under conditional conditions. 20. DISTRIBUTION/AVAILABILITY OF ABSTRA QUINCLASSIFIED/UNLIMITED SAME A	of DIGL-RP solid prome Mutagenicity To ranging from 5 mg, litions of this test	ropellant wa est. Tester /plate to 0.	strains T 0016 mg/pl	A97, TA9	8, TA100, and
22a. NAME OF RESPONSIBLE INDIVIDUAL		226 TELEPHONE	(Include Area Co		
Edwin S. Beatrice, COL, M	IC	415-56	1-3600		SGRD-UL-Z

DD Form 1473, JUN 86


Previous editions are obsolete.

SECURITY CLASSIFICATION OF THIS PAGE

UNCLASSIFIED

ABSTRACT

The mutagenic potential of DIGL-RP solid propellant was assessed by using the Ames Salmonella/Mammalian Microsome Mutagenicity Test. Tester strains TA97, TA98, TA100, and TA102 were exposed to doses ranging from 5 mg/plate to 0.0016 mg/plate. The test compound was not mutagenic under conditions of this test.



PREFACE

TYPE REPORT: Ames Test GLP Study Report

TESTING FACILITY:

US Army Medical Research and Development Command Letterman Army Institute of Research Presidio of San Francisco, CA 94129-6800

SPONSOR:

US Army Medical Research and Development Command US Army Biomedical Research and Development Laboratory Fort Detrick, Frederick, MD 21701-5012 Project Officer: Gunda Reddy, PhD

PROJECT/WORK UNIT/APC: #3E162720A835/180/TLB0

GLP STUDY NUMBER: 85014

STUDY DIRECTOR: MAJ Don W. Korte Jr., PhD, MSC

PRINCIPAL INVESTIGATOR: SGT Steven K. Sano, BA

REPORT AND DATA MANAGEMENT: A copy of the final report,

study protocol, retired stability

and purity data on the test

compound, tissues, and an aliquot of the test compound will be retained

in the LAIR Archives.

TEST SUBSTANCE: DIGL-RP Solid Propellant

INCLUSIVE STUDY DATES: 19 Aug - 14 Sep 85

OBJECTIVE: The objective of this study was to determine the mutagenic potential of DIGL-RP solid propellant (LAIR Code TP057) by using the Ames Salmonella/Mammalian Microsome Mutagenicity Test.

ACKNOWLEDGMENTS

CPT John W. Harbell, PhD, MSC; SGT Lillie D. Witcher, BS; SP4 John R.G. Ryabik, BS; Mr. John Dacey; and Ms. Joanne Wong provided research assistance.

SIGNATURES OF PRINCIPAL SCIENTISTS INVOLVED IN THE STUDY

We, the undersigned, declare that GLP study number 85014 was performed under our supervision, according to the procedures described herein, and that this report is an accurate record of the results obtained.

DON W. KORTE JR,

MAJ, MSC

Study Director

Analytical chemist

STEVEN K. SANO, BA / DATE

SGT, USA

Principal Investigator

DEPARTMENT OF THE ARMY

LETTERMAN ARMY INSTITUTE OF RESEARCH PRESIDIO OF SAN FRANCISCO, CALIFORNIA 94129-6800

REPLY TO ATTENTION OF:

SGRD-ULZ-QA (70-ln)

15 September 1988

MEMORANDUM FOR RECORD

SUBJECT: GLP Compliance for GLP Study 85014

This is to certify that in relation to LAIR GLP Study 85014, the following inspections were made:

16 August 1985

Protocol ReviewPlate Incorporation 11 September 1985 - Plate Incorpora 13 September 1985 - Plate Counting

2. The institute report entitled "Mutagenic Potential of DIGL-RP Solid Propellant in the Ames Salmonella/Mammalian Microsome Mutagenicity Test, " Toxicology Series 150, was audited on 20 July 1988.

Carolyn M. LEWIS

Chief, Quality Assurance

TABLE OF CONTENTS

Abstracti
Prefaceiii
Acknowledgmentsiv
Signatures of Principal Scientistsv
Report of the Quality Assurance Unitvi
Table of Contentsvii
BODY OF THE REPORT
INTRODUCTION1
Objective of the Study2
MATERIALS AND METHODS2
Test Compound
RESULTS5
DISCUSSION9
CONCLUSION9
REFERENCES10
APPENDIX11
Appendix A. Chemical Data
OFFICIAL DISTRIBUTION LIST

Mutagenic Potential of DIGL-RP Solid Propellant in the Ames Salmonella/Mammalian Microsome Mutagenicity Test-Sano and Korte

INTRODUCTION

The Department of Defense is considering the use of diethyleneglycol dinitrate (DEGDN), triethyleneglycol dinitrate (TEGDN), or trimethylolethane trinitrate (TMETN) as a replacement for nitroglycerin in munition formulations. "health effects" review conducted for the US Army Biomedical Research and Development Laboratory (USABRDL) identified numerous gaps in the toxicology database of these compounds Consequently, USABRDL has tasked the Division of Toxicology, LAIR, to conduct an initial evaluation of the health effects of DEGDN, TMETN, TEGDN, and two DEGDN-based propellants, JA-2 and DIGL-RP. This initial evaluation includes the Ames mutagenicity test, acute oral toxicity tests in rats and mice, acute dermal toxicity tests in rabbits, dermal and ocular irritation studies in rabbits, and dermal sensitization studies in guinea pigs. This report contains the results of a study that assessed the mutagenic potential of DIGL-RP in the Ames Salmonella/Mammalian Microsome Mutagenicity Test.

The Ames Salmonella/Mammalian Microsome Mutagenicity Test is a short-term screening test that utilizes histidine auxotrophic mutant strains of Salmonella typhimurium to detect compounds that are potentially mutagenic in mammals. A mammalian microsomal enzyme system is incorporated in the test to increase sensitivity by simulating in vivo metabolic activation of the test compound. The Ames test is an inexpensive yet highly predictive and reliable test for detecting mutagenic activity and thus carcinogenic potential (2).

This evaluation of DIGL-RP utilizes a revision of the Ames Salmonella/Mammalian Microsome Mutagenicity Test (3). Two new tester strains, a frame-shift strain (TA97) and a strain carrying an ochre mutation on a multicopy plasmid (TA102), are added to the standard tester set. TA97 replaces TA1537, TA1535 and TA1538 which are removed from the recommended set. TA98 and TA100 are retained.

Objective of the Study

The objective of this study was to determine the mutagenic potential of DIGL-RP solid propellant (LAIR Code TP057) by using the revised Ames Salmonella/Mammalian Microsome Mutagenicity Test.

MATERIALS AND METHODS

Test Compound

Compound name: DIGL-RP Solid Propellant

Code number: LAIR Code No. TP057

Physical state: Solid

Source: Hercules Incorporated Wilmington, Delaware

Storage: DIGL-RP was received from Radford Army Ammunition Plant (Radford, VA) and assigned the LAIR Code number TP057. The test compound was stored at room temperature (21°C) until used.

Chemical Properties/Analysis: Data provided by Hercules Inc., characterizing the chemical composition and purity of the test material, are presented in Appendix A along with confirmatory analysis of the test material performed by the Division of Toxicology, LAIR (Presidio of San Francisco, CA).

Test Solvent

The positive control chemicals and the test compound were dissolved in grade I dimethyl sulfoxide (lot 113F-0450) obtained from Sigma Chemical Co. (St. Louis, MO).

Chemical Preparation

DIGL-RP was stored at room temperature (21°C) until used. The solid propellant was ground into a fine powder with a liquid nitrogen freezer/mill Model # 6700 (Spex Industries). On the day of dosing, 300 mg of the test compound was measured into a sterile vial and dissolved in 6 ml of grade I dimethyl sulfoxide to achieve a 5% (w/v) solution. Aliquots of this solution were used to dose the test plates.

Test Strains

Salmonella strains TA97, TA98, TA100, and TA102, obtained directly from Dr. Bruce Ames, University of California, Berkeley, were used. These strains were maintained in our laboratory at -80°C . Quality control tests were run concurrently with the test substance to establish the validity of their special features and to determine the spontaneous reversion rate. Descriptions of the strains, their genetic markers, and the methods for strain validation are given in the LAIR SOP, OP-STX-1 (4).

Test Format

DIGL-RP was evaluated for mutagenic potential according to a revised Ames method (3). A detailed description of the methodology is given in LAIR SOP, OP-STX-1 (4).

Toxicity Tests

Toxicity tests were conducted to determine a sublethal concentration of the test substance. This toxicity level was found by using minimal glucose agar (MGA) plates, concentrations of DIGL-RP ranging from 1.6 x 10-3 mg/plate to 5 mg/plate, and approximately 108 cells of TA100 per plate. Top agar containing trace amounts of histidine and biotin was placed on the plates. Strain verification was confirmed on the bacteria, along with a determination of the spontaneous reversion rate. After incubation, the growth on the plates was observed. Since none of the plates showed a decrease in the number of macrocolonies (below the number in the spontaneous reversion plates) or an observable reduction in the density of the background lawn, a maximum "limit" dose of 5 mg/plate was used in the mutagenicity test.

Mutagenicity Test

The test substance was evaluated over a 1000-fold range of concentrations, decreasing from the minimum toxic level (the maximum or limit dose) by a dilution factor of 5, both with and without 0.5 ml of the S-9 microsome fraction. The S-9 was purchased from Microbiological Associates Inc. (Bethesda, MD). The optimal titer of this S-9, as determined by Microbiological Associates Inc., was 0.75 mg protein/plate. After all the ingredients were added, the top agar was mixed, then overlaid on MGA plates. These plates contained 2% glucose and Vogel Bonner "E" Concentrate (5). The water used in this medium and in all reagents came from a Technic Model 301 Reverse Osmosis Pre-Treatment Water System (Seattle, WA), LAIR SOP, OP-STX-94 (6). Plates were

incubated upside down in the dark at 37°C for 72 hr. Plates were prepared in triplicate and the average revertant counts were recorded. The average number of revertants at each dose level was compared to the average number of spontaneous revertants (negative control). The spontaneous reversion rate (with and without S-9) was monitored by averaging the counts from two determinations run simultaneously with the test compound. The spontaneous reversion rate was determined by inoculating one set of plates before and one set after the test compound plates so that any change in spontaneous reversion rate during the dosing procedure would be detected. This spontaneous reversion rate was also compared with historical values for this laboratory and those cited in Maron and Ames (3). Sterility and strain verification controls were run concurrently. All reagents, test compounds, and media were checked for sterility by plating samples of each on MGA media and incubating them at 37°C with the test plates. The Salmonella strains were verified by a standard battery of tests. The integrity of the different Salmonella strains used in the assay was verified by the following standard tests:

-Lack of growth (inhibition) in the presence of crystal violet which indicates that the prerequisite alteration of the lipopolysaccharide layer of the cell wall is present.

-Growth in the presence of ampicillin-impregnated disks which indicates the presence of an ampicillin-resistant R Factor.

-Lack of growth (inhibition) following exposure to ultraviolet light which indicates the absence of the DNA excision-repair mechanism (for all strains except TA102).

Four known mutagens were tested as positive controls to confirm the responsiveness of the strains to the mutation process. Each strain must be tested with at least one positive control but may be tested with several. These compounds, benzo[a]pyrene, 2-aminofluorene, 2-aminoanthracene and 4-nitroquinoline-n-oxide, were obtained from Sigma Chemical Co. (St. Louis, MO). The test compound and mutagens were handled during this study in accordance with the standards published in NIH <u>Guidelines for the Laboratory Use of Chemical Carcinogens</u> (DHHS Publication No. (NIH) 81-2385, May 1981).

Data Interpretation

According to Brusick (7), a compound is considered mutagenic if a positive dose response (correlated dose response) over three dose concentrations is achieved with at least the highest dose yielding a revertant colony count greater than or equal to twice the spontaneous colony count for the tester strains TA98 and TA100. A strong correlated dose response in strain TA100 without a doubling of the individual colony count may also be considered positive.

Maron and Ames (3) consider a compound mutagenic in tester strains TA97 and TA102 if a correlated dose response over three concentrations is achieved with the highest dose yielding a revertant colony count greater than or equal to twice the spontaneous colony count.

Deviations/Changes

A 72-hr rather than a 48-hr incubation period was used. According to Maron (personal communication, 1985), the additional 24-hr growth enables all of the revertant colonies, especially TA102, to be detected with the colony counter.

Storage of Raw Data and Final Report

A copy of the final report, study protocols, raw data, SOPs, and an aliquot of the test compound will be retained in the LAIR archives.

RESULTS

On 23 August 1985, the toxicity of DIGL-RP was determined (Table 1). For this experiment all sterility, strain verification, and negative controls were normal (Table 1). No toxicity was observed after exposure of the tester strain (TA100) to the highest dose used (5 mg/plate).

Normal results were obtained for all sterility and strain verification tests during the Ames Test performed on 27-30 August 1985 (Table 2). DIGL-RP did not induce any appreciable increase in the revertant colony counts relative to those of the negative control cultures (Table 3).

A copy of the raw data is included in Appendix B.

TABLE 1: TOXICITY DETERMINATION FOR DIGL-RP

GT.P	STUDY	NUMBER	85014	23	Αιισ	1985	PERFORMED	BY	SANO/WONG
		******	~~~.	~ ~					01210/110110

TOXICITY	DETERMINATION	REVERTANT	PI.ATE	COUNT	$(T\Delta 100)$
IUNICIII	DETERMITING	TATE A DISTANTA		COOMI	(1771)

CONCENTRATION OF TEST COMPOUND	MEAN	(1SD)	BACKGROUND LAWN*
START RUN NEGATIVE CONTROL	102	(14.0)	NL
5.0 mg/plate	67	(6.6)	NL
1.0 mg/plate	71	(7.2)	NL
0.2 mg/plate	83	(11.1)	NL
0.04 mg/plate	77	(10.1)	NL
0.008 mg/plate	86	(1.2)	NL
0.0016 mg/plate	91	(8.3)	NL
END RUN NEGATIVE CONTROL	96	(8.1)	NL

STRAIN VERIFICATION FOR TOXICITY DETERMINATION (TA100)

HISTIDINE REQUIREMENT	NG*	•
AMPICILLIN RESISTANCE	G	
UV	NG	
CRYSTAL VIOLET		
SENSITIVITY (ZONE SIZE)	NG	(12mm)
STERILITY CONTROL	NG	

STERILITY CONTROL FOR TOXICITY DETERMINATION

MATERIAL TESTED	OBSERVATION*
MINIMAL GLUCOSE AGAR PLATES TOP AGAR DILUENT WATER NUTRIENT BROTH TEST COMPOUND (HIGHEST DOSE)	NG NG NG NG NG

^{*} NL = Normal Lawn G = Growth NG = No Growth

TABLE 2: STRAIN VERIFICATION AND STERILITY TESTING FOR THE MUTAGENICITY DETERMINATION OF DIGL-RP (TP057)

GLP STUDY NUMBER 85014 12 SEP 1985 PERFORMED BY SANO/WONG

STRAIN VERIFICATION

		OBSEF	RVATIONS*	
STRAINS	TA97	TA98	TA 10	0 TA102
HISTIDINE REQUIREMENT	NG	NG	NG	NG
AMPICILLIN RESISTANCE	G	G	G	G
UV REPAIR	NG	NG	NG	G
CRYSTAL VIOLET				
SENSITIVITY	NG	NG	NG	NG
(ZONE SIZE)	(12mm)	(10mm)	(12mm)	(12mm)
STERILITY CONTROL	NG	NG	NG	NG

STERILITY CONTROL FOR MUTAGENICITY DETERMINATION

MATERIAL TESTED	OBSERVATION*
MINIMAL GLUCOSE AGAR PLATES TOP AGAR DILUENT WATER NUTRIENT BROTH TEST COMPOUND (HIGHEST DOSE)	NG NG NG NG NG

^{*} NL = Normal Lawn G = Growth NG = No Growth

NEG CONTROL O.0 mg/ml E. O.00 mg/ml E.		TABLE 3:	MUTA(MUTAGENICITY	ASSAX	FOR	DIGL-RP (TP0	(TP057) †
### Properties of the color of	STUDY NUMBE	8501	DATE:	2			i	SANO/WONG
WITHOUT S-9 CONTROL 0.0 mg/ml 61 (7.4) 28 (1.3) 106 (14.7) 153 (19.5) 2.0 μg/ml 72 (6.7) 278 (28.0) 1229 (69.3) 1189 (94.5) 5.0 mg/plate 67 (6.1) 24 (5.6) 83 (4.6) 125 (4.6) 0.04 mg/plate 66 (0.6) 21 (3.0) 83 (7.0) 111 (8.6) 0.008 mg/plate 56 (3.8) 22 (4.9) 80 (6.1) 119 (9.2) 0.0016 mg/plate 56 (3.8) 22 (4.9) 80 (6.1) 130 (13.8) 0.0016 mg/plate 56 (3.8) 27 (6.0) 94 (14.3) 173 (51.2) 2.0 μg/ml 65 (3.9) 27 (6.0) 94 (14.3) 173 (51.2) 2.0 μg/ml 172 (4.0) 1654 (44.3) 173 (8.6) 2.0 2.0 μg/ml 65 (3.9) 27 (6.0) 94 (14.3) 173 (51.2) 2.0 μg/ml 172 (4.0) 1654 (44.3) 1792 (88.6) 2.0 5.0 mg/plate 66 (4.6) 26 (4.4) 97 (4.0) 210 (14.3) 1.0 mg/plate 62 (6.7) 24 (3.6) 90 (11.6)	COMPOUND	DOSE		TA97		TA98	TA100	TA102
2.0 μg/ml 3.0 mg/plate 67 (6.1) 67 (6.1) 27 (5.8) 1.0 mg/plate 60 (0.6) 60 (0				WITH	S	6		
2.0 \(\mu \frac{\mu \gamma}{\mu \gamma} \) \(\begin{array}{c} \frac{\mu \gamma}{\mu \gamma} \\	_	0.0 mg/	61	(7.	28	H	06 (14	73 /10
ONTROL 0.0 mg/plate 67 (6.1) 24 (5.6) 83 (4.6) 125 (4.6) 0.2 mg/plate 64 (5.0) 19 (1.0) 90 (6.1) 119 (9.0.4 mg/plate 66 (3.8) 22 (4.9) 83 (7.0) 111 (8.0.4 mg/plate 56 (3.8) 22 (4.9) 80 (1.5) 130 (13.0.4 mg/plate 51 (8.0) 24 (9.7) 89 (6.1) 143 (9.13.0.4 mg/plate 66 (4.6) 22 (4.4) 97 (4.0) 1792 (88.6) 2.0 µg/ml 172 (4.0) 1654 (44.3) 1118 (74.5) 289 (31.0.4) 1.0 mg/plate 62 (18.8) 22 (1.5) 81 (16.3) 196 (5.0.4 mg/plate 62 (6.7) 22 (1.5) 81 (16.3) 164 (20.00 mg/plate 63 (5.0) 22 (3.5) 90 (11.6) 156 (29.00 mg/plate 68 (4.2) 28 (4.7) 79 (19.3) 164 (20.13.9) 162 (13.9)	TDOE T	, p u g/	72	9	1	ထ	229 (69)	189 /84
ONTROL 0.0 mg/ml 65 (3.9) 27 (6.0) 90 (6.1) 119 (9.000 mg/plate 56 (3.8) 22 (4.9) 80 (1.5) 119 (9.000 mg/plate 56 (3.8) 22 (4.9) 80 (1.5) 130 (13.0) 10.0016 mg/plate 51 (8.0) 24 (9.7) 89 (6.1) 143 (9.0016 mg/plate 51 (8.0) 24 (9.7) 89 (6.1) 143 (9.0016 mg/plate 62 (18.8) 22 (4.4) 97 (4.0) 2.0 µg/ml 172 (4.0) 1654 (44.3) 1118 (74.5) 289 (31.000 mg/plate 62 (18.8) 22 (1.5) 81 (16.3) 196 (5.000 mg/plate 62 (6.7) 22 (1.5) 81 (16.3) 196 (5.000 mg/plate 62 (6.7) 22 (3.5) 84 (19.3) 164 (20.00 mg/plate 60 (8.4) 25 (8.5) 84 (19.3) 164 (20.1) 165 (13.5) 165 (13.5) 165 (13.5) 162 (13.5) 165 (13.5)	15037 75097	Ĕ i	67	(6	24	5.	83 (4.	125 (34.
ONTROL 0.04 mg/plate 56 (3.8) 22 (4.9) 83 (7.0) 111 (8. 0.04 mg/plate 56 (3.8) 22 (4.9) 80 (1.5) 130 (13. 0.008 mg/plate 51 (8.0) 24 (9.7) 89 (6.1) 143 (9. 13. 0.0016 mg/plate 51 (8.0) 24 (9.7) 89 (6.1) 143 (9. 13. 0.0016 mg/plate 62 (18.8) 22 (1.5) 81 (16.3) 196 (5.0) 0.008 mg/plate 62 (6.7) 22 (3.5) 81 (16.3) 196 (5.0) 0.008 mg/plate 68 (4.2) 22 (3.5) 84 (19.3) 164 (20.1) 166 (4.7) 79 (19.3) 164 (20.1) 166 (19.3) 166 (2.6) 191 (20.1) 166 (3.6) 191 (20.1) 1	TP057		40	S	19	•	0 (6.	19 (9.
ONTROL 0.0 mg/ml 65 (3.8) 22 (4.9) 80 (1.5) 130 (13. 8) 0.0016 mg/plate 56 (3.8) 24 (9.7) 89 (6.1) 143 (9. 80 (1.5) 130 (13. 8) 0.0016 mg/plate 62 (18.8) 27 (1.5) 118 (74.5) 289 (31. 2.0 µg/ml 172 (4.0) 1654 (44.3) 1118 (74.5) 289 (31. 2.0 µg/ml 172 (4.0) 1654 (44.3) 1128 (74.5) 289 (31. 2.0 µg/ml 172 (4.0) 1654 (44.3) 1128 (74.5) 289 (31. 2.0 µg/ml 1.0 mg/plate 62 (18.8) 22 (1.5) 81 (16.3) 196 (5.9 (1.5) 0.008 mg/plate 62 (6.7) 24 (3.5) 90 (11.6) 156 (29.0 (1.3) 0.0016 mg/plate 60 (8.4) 25 (8.5) 84 (19.3) 164 (20.1) 162 (13.9)	TP057	0.4	9 6	:	$\frac{21}{1}$	•	3 (7.	11 (8.
MITH S-9 ONUTROL 0.0 mg/ml 65 (3.9) 27 (6.0) 94 (14.3) 173 (51. 2.0 µg/ml 172 (4.0) 1754 (89.7) 89 (6.1) 143 (9. 3.0) 2.0 µg/ml 172 (4.0) 1654 (44.3) 1118 (74.5) 289 (31. 3.0 µg/ml 1.0 mg/plate 62 (18.8) 22 (1.5) 81 (16.3) 196 (5.9) 0.0 mg/plate 62 (6.7) 24 (3.6) 89 (2.6) 191 (20.0 0.008 mg/plate 60 (8.4) 25 (8.5) 84 (19.3) 164 (20.1) 165 (13.5) 165 (13.5) 164 (19.3) 164 (20.1) 165 (13.5) 165	TP057	008		υ :	52 52		0 (11.	09 (19.
NITH S-9 ONTROL 0.0 mg/ml 65 (3.9) 27 (6.0) 94 (14.3) 173 (51. 2.0 µg/ml 172 (4.0) 1654 (44.3) 1118 (74.5) 289 (31. 2.0 µg/ml 2.0 µg/ml 1754 (89.7) 1792 (88.6) 5.0 mg/plate 62 (18.8) 22 (1.5) 81 (16.3) 196 (5.9 (0.04 mg/plate 62 (6.7) 22 (1.5) 89 (2.6) 191 (20.0 0.008 mg/plate 60 (8.4) 25 (8.5) 84 (19.3) 164 (20.1 3.9 (19.2) 162 (13.9 2.9) (19.2) 162 (13.9 2.9)	TP057	.0016 mg/		<u>,</u> ∞	22	•		30 (13.
NITH S-9 ONTROL 0.0 mg/ml 65 (3.9) 27 (6.0) 94 (14.3) 173 (51. 2.0 \(\mug/ml\) 2.0 \(\mug/ml\) 172 (4.0) 1654 (44.3) 1118 (74.5) 289 (31. 2.0 \(\mug/ml\) 2.0 \(\mug/ml\) 2.0 \(\mug/plate\) 66 (4.6) 26 (4.4) 97 (4.0) 210 (14. 5.0 \(\mug/plate\) 2.0 \(\mug/plate\) 62 (18.8) 22 (1.5) 81 (16.3) 196 (5.0) 0.2 \(\mug/plate\) 62 (6.7) 24 (3.6) 89 (2.6) 191 (20.0) 0.008 \(\mug/plate\) 62 (6.7) 24 (3.5) 90 (11.6) 164 (20.0) 162 (13.5) 84 (19.3) 164 (20.1) 162 (13.2) 162 (13.2)		•		•	r J	•	(6.	43 (9.
ONTROL 0.0 mg/ml 65 (3.9) 27 (6.0) 94 (14.3) 173 (51. 2.0 µg/ml 172 (4.0) 1654 (44.3) 1118 (74.5) 289 (31. 2.0 µg/ml 2.0 µg/ml 1754 (89.7) 1792 (88.6) 2.0 mg/plate 66 (4.6) 26 (4.4) 97 (4.0) 210 (14. 1.0 mg/plate 62 (18.8) 22 (1.5) 81 (16.3) 196 (5.0) 0.2 mg/plate 63 (6.7) 24 (3.6) 89 (2.6) 191 (20. 0.00 mg/plate 60 (8.4) 25 (8.5) 84 (19.3) 164 (20. 0.0016 mg/plate 68 (4.2) 28 (4.7) 79 (19.2) 162 (13.				WIT	S			
2.0 µg/ml 172 (4.0) 1654 (44.3) 1118 (74.5) 173 (51. 2.0 µg/ml 2.0 µg/ml 1754 (89.7) 1792 (88.6) 289 (31. 2.0 µg/ml 66 (4.6) 26 (4.4) 97 (4.0) 210 (14. 0.2 mg/plate 62 (18.8) 22 (1.5) 81 (16.3) 196 (5.0) 0.2 mg/plate 63 (5.0) 22 (3.5) 90 (11.6) 156 (29. 0.008 mg/plate 60 (8.4) 25 (8.5) 84 (19.3) 164 (20. 0.0016 mg/plate 68 (4.2) 28 (4.7) 79 (19.3) 164 (20. 13.0) 162 (13.0)		0.	65		27		•	
2.0 µg/ml 2.0 µg/ml 2.0 µg/ml 2.0 µg/ml 3.0 mg/plate 66 (4.6) 26 (4.4) 97 (4.0) 210 (14.0) 1.0 mg/plate 62 (18.8) 22 (1.5) 81 (16.3) 196 (5.0) 0.2 mg/plate 63 (5.0) 22 (3.5) 90 (11.6) 156 (29.0) 0.008 mg/plate 60 (8.4) 25 (8.5) 84 (19.3) 164 (20.0) 0.0016 mg/plate 68 (4.2) 28 (4.7) 79 (19.2) 162 (13.0)	AF*	٥.	7	• ,	ט ו	· <	74 (14.	73 (51.
2.0 µg/ml 5.0 mg/plate 66 (4.6) 26 (4.4) 1792 (88.6) 1.0 mg/plate 62 (18.8) 22 (1.5) 81 (16.3) 196 (5.0) 0.2 mg/plate 62 (6.7) 24 (3.6) 89 (2.6) 191 (20.0) 0.04 mg/plate 60 (8.4) 25 (3.5) 90 (11.6) 156 (29.0) 0.008 mg/plate 60 (8.4) 25 (8.5) 84 (19.3) 164 (20.0) 0.0016 mg/plate 68 (4.2) 28 (4.7) 79 (19.2) 162 (13.0)	BP*	0		•	ייני פייני פייני	r (118 (/4.	89 (31.
5.0 mg/plate 66 (4.6) 26 (4.4) 97 (4.0) 210 (14. 1.0 mg/plate 62 (18.8) 22 (1.5) 81 (16.3) 196 (5.0) 0.2 mg/plate 62 (6.7) 24 (3.6) 89 (2.6) 191 (20. 0.00 mg/plate 60 (8.4) 25 (3.5) 90 (11.6) 156 (29. 0.0016 mg/plate 68 (4.2) 28 (4.7) 79 (19.3) 164 (20. 13.0)	AA*	0			715	, ,	523 (10.	
1.0 mg/plate 62 (18.8) 22 (1.5) 81 (16.3) 196 (5.0) 0.2 mg/plate 62 (6.7) 24 (3.6) 89 (2.6) 191 (20.00 mg/plate 63 (5.0) 22 (3.5) 90 (11.6) 156 (29.0008 mg/plate 60 (8.4) 25 (8.5) 84 (19.3) 164 (20.0016 mg/plate 68 (4.2) 28 (4.7) 79 (19.2) 162 (13.0016 mg/plate 68 (4.2) 28 (4.7) 79 (19.2) 162 (13.0016 mg/plate 68 (4.2) 28 (4.7)	TP057	C	99		0 0	۷.	792 (88.	
0.2 mg/plate 62 (6.7) 24 (3.6) 81 (16.3) 196 (5.0) 0.04 mg/plate 63 (5.0) 22 (3.5) 90 (11.6) 156 (29.0.008 mg/plate 60 (8.4) 25 (8.5) 84 (19.3) 164 (20.0.0016 mg/plate 68 (4.2) 28 (4.7) 79 (19.2) 162 (13.0.0016 mg/plate 68 (4.2) 28 (4.7) 29 (19.2)	TP057		9 6	٠	97	•	7 (4.	10 (14.
0.04 mg/plate 62 (6.7) 24 (3.6) 89 (2.6) 191 (20.6) 0.04 mg/plate 63 (5.0) 22 (3.5) 90 (11.6) 156 (29.0) 0.008 mg/plate 60 (8.4) 25 (8.5) 84 (19.3) 164 (20.0) 0.0016 mg/plate 68 (4.2) 28 (4.7) 79 (19.2) 162 (13.0)	TP057	, (79	•	22		1 (16.	(5)
0.004 mg/plate 63 (5.0) 22 (3.5) 90 (11.6) 156 (29. 0.008 mg/plate 60 (8.4) 25 (8.5) 84 (19.3) 164 (20. 0.0016 mg/plate 68 (4.2) 28 (4.7) 79 (19.2) 162 (13.	おひのにつ	, (79	٠	24		6	91 720
0.008 mg/plate 60 (8.4) 25 (8.5) 84 (19.3) 164 (20.0016 mg/plate 68 (4.2) 28 (4.7) 79 (19.2) 162 (13.	1100.1	Ĕ 50.			22		7 / 1	
0.0016 mg/plate 68 (4.2) 28 (4.7) 79 (19.2) 164 (20.	TPU5/	800			25		777	20 (2%.
701 701 (7:/1)	/ CO.J.	.0016			28		. 65.	64 (20.
								02 (13.

† Values represent the mean number of revertants/plate (\pm standard deviation) * NQNO = 4-nitroquinoline-n-oxide, AF = 2-aminofluorene, BP = benzo(a)pyrene, AA = 2-aminoanthracene

DISCUSSION

Certain test criteria must be satisfied before an Ames test can be considered a valid assessment of a compound's mutagenic potential. First, the special features of the Ames strains must be verified. These features include demonstration of ampicillin resistance, alterations in the LP layer, and deficiency in DNA excision-repair (except TA102). Second, the Salmonella strains must be susceptible to mutation by known mutagens. Third, the optimal concentration of the test compound must be determined by treating TA100 with a broad range of doses and observing the potential toxic effects on formation of macrocolonies and microcolonies. If these tests are performed and expected data are obtained, then the results of the Ames test can be considered valid.

After validation of bacterial strains and selection of optimal sublethal doses, DIGL-RP was evaluated in the Ames test. Criteria for a positive response are a correlated dose-response relationship and a twofold increase in revertant colony counts relative to the respective negative control counts (3,4,7). DIGL-RP did not induce the requisite dose-response relationship or the increase in revertant colony counts necessary for a positive response. Thus, the results of this test indicate that DIGL-RP is not mutagenic when evaluated in the Ames test.

CONCLUSION

DIGL-RP was evaluated for mutagenic potential in the Ames Test, both in the presence and absence of metabolic activation, and did not induce a positive mutagenic response under conditions of this study.

REFERENCES

- 1. Holleman JW, Ross RH, Carroll JW. Problem definition study on the health effects of diethyleneglycol dinitrate, triethyleneglycol dinitrate, and trimethylolethane trinitrate and their respective combustion products. Frederick, Maryland: US Army Medical Bioengineering Research and Development Laboratory, 1983, DTIC No. ADA 127846.
- 2. Ames BN, McCann J, Yamasaki E. Methods for detection of carcinogens and mutagens with Salmonella/Mammalian Microsome Mutagenicity Test. Mutation Res 1975;31:347-364.
- 3. Maron DM, Ames BN. Revised methods for the Salmonella Mutagenicity Test. Mutation Res 1983;113:173-215.
- 4. Ames Salmonella/Mammalian Microsome Mutagenesis Test.
 LAIR Standard Operating Procedure OP-STX-1, Presidio of
 San Francisco, California: Letterman Army Institute of
 Research, 15 November 1983.
- 5. Vogel HJ, Bonner DM. Acetylornithinase of *E. coli*: Partial purification and some properties. J Biol Chem 1956;218:97-106.
- 6. Operation of the Technic Model 301 Reverse Osmosis Pre-Treatment Water System and the Corning Model MP-1 Glass Still. LAIR Standard Operating Procedure OP-STX-94, Presidio of San Francisco, California: Letterman Army Institute of Research, 29 July 1985.
- 7. Brusick D. Genetic toxicology. In: Hayes AW, ed. Principles and methods of toxicology. New York: Raven Press, 1982:223-272.

Appendix A.	Chemical Data	2
Appendix B.	Individual Plate Scores	4

Appendix A: CHEMICAL DATA

Name of Test Substance: DIGL-RP Solid Propellant

Composition/Analytical Data: See appended data sheet for

information supplied by source

LAIR Code No.: TP057

Physical State: Solid Black Cylinders

Preparation of Test Substance for Dosing:

The cylinders of DIGL were ground to a fine powder under liquid nitrogen using a Spex freezer mill. After grinding, the powder was seived through an 80-mesh screen and dissolved in DMSO.

Source: Radford Army Ammunition Plant, Radford, Virginia (prime contractor: Hercules Inc., Wilmington, Delaware).

Lot No.: RAD83M001S169

Appendix A (cont.): CHEMICAL DATA

DATA SHEET

FORMULA

DIGL-RP

Ingredient	Finished Propellant Percentage
Nitrocellulose 13.10% ± 0.05% Nitrogen 6-12 seconds viscosity	62.50 ± 2.00
Diethyleneglycol Dinitrate (DEGDN)	36.70 ± 1.50
Ethyl Centralite (EC)	0.25 0.25 ± 0.05
Akardit II	0.25 0.45 ± 0.20
Magnesium Oxide	0.05 Max
Graphite (Chg 5)	0.05 Max

TOTAL: 100.00

Appendix B: INDIVIDUAL PLATE SCORES

TOXICITY DETERMINATION WITH TA100						
COMPOUND	DOSE/p	late	PLATE 1	PLATE 2	PLATE 3	
NEGATIVE CONTR	ROL		116	88	102	
TP057	5.0	mg	60	68	73	
TP057	1.0	mg	69	79	65	
TP057	0.2	mg	71	85	93	
TP057	0.04	mg	76	68	88	
TP057	0.008	mg	87	85	85	
TP057	0.0016	mg	94	98	82	
NEGATIVE CONTE (End Run)	ROL		101	87	101	

Appendix B (cont.): INDIVIDUAL PLATE SCORES

	MUTAGENICITY T	ESTS WITH	OUT S-9		
COMPOUND	DOSE/plate	TA97	TA98	TA100	TA102
NEG CONTROL (start run)		70 53 61	27 30 30	93 100 111	150 128 158
NEG CONTROL (END RUN)		53 59 69	29 25 28	130 113 91	145 153 186
NQNO*	2.0 µ g	76 75 64	257 268 310	1156 1237 1294	1294 1111 1163
TP057	5.0 mg	70 71 60	18 25 29	84 78 87	130 125 121
TP057	1.0 mg	59 63 69	20 18 19	95 91 83	123 108 126
TP057	0.2 mg	59 60 60	24 21 18	80 78 91	120 108 104
TP057	0.04 mg	80 70 73	17 30 28	83 66 60	98 132 97
TP057	0.008 mg	54 53 60	24 16 25	81 78 80	122 123 145
TP057	0.0016 mg	43 50 59	13 26 32	9 4 82 90	153 134 143

^{* 4-}nitroquinoline-n-oxide

Appendix B (cont.): INDIVIDUAL PLATE SCORES

MUTAGENICITY TESTS WITH S-9						
COMPOUND	DOSE/p	late	TA97	TA98	TA100	TA102
NEG CONTROL (Start Run)			66 59 70	21 24 25	90 122 91	213 221 224
NEG CONTROL (End Run)			63 64 68	36 33 23	88 81 91	121 126 130
2-aminofluorene	2.0	μg	168 173 176	1702 1644 1615	1035 1140 1179	264 278 324
benzo[a]pyrene	2.0	μg		309 412 516	526 531 511	
2-aminoanthracene	2.0	μg		1847 1746 1668	1819 1693 1864	
TP057	5.0	mg	63 63 71	31 24 23	93 96 101	210 196 225
TP057	1.0	mg	72 73 40	21 22 24	87 63 94	198 200 189
TP057	0.2	mg	70 59 58	20 27 25	90 91 86	208 196 169
TP057	0.04	mg	68 63 58	24 24 18	78 101 92	185 156 127
TP057	0.008	mg	65 64 50	24 34 17	96 62 95	187 155 150
TP057	0.0016	mg	63 69 71	30 32 23	58 96 82	174 166 147

Distribution List

Commander
US Army Biomedical Research and
Development Laboratory (27)
ATTN: SGRD-UBZ-C
Fort Detrick, Frederick, MD 21701-5010

Defense Technical Information Center (DTIC) (2)
ATTN: DTIC-DLA
Cameron Station
Alexandria, VA 22304-6145

US Army Medical Research and Development Command (2) ATTN: SGRD-RMI-S Fort Detrick, Frederick, MD 21701-5012

Commandant Academy of Health Sciences, US Army ATTN: AHS-CDM Fort Sam Houston, TX 78234

Chief
USAEHA Regional Division, West
Fitzsimmons AMC
Aurora, CO 80045

Chief USAEHA Regional Division, North Fort George G. Meade, MD 20755

Chief USAEHA Regional Division, South Bldg. 180 Fort McPherson, GA 30330

Commander
USA Health Services Command
ATTN: HSPA-P
Fort Sam Houston, TX 78234

Commandant
Academy of Health Sciences
United States Army
ATTN: Chief, Environmental
Quality Branch
Preventive Medicine Division
(HSHA-IPM)
Fort Sam Houston, TX 78234

Commander US Army Materiel Command ATTN: AMSCG 5001 Eisenhower Avenue Alexandria, VA 22333

Commander
US Army Environmental Hygiene
Agency
ATTN: Librarian, HSDH-AD-L
Aberdeen Proving Ground, MD 21010

Dean
School of Medicine
Uniformed Services University of the
Health Sciences
4301 Jones Bridge Road
Bethesda, MD 20014

Commander
US Army Materiel Command
ATTN: AMCEN-A
5001 Eisenhower Avenue
Alexandria, VA 22333

HQDA ATTN: DASG-PSP-E Falls Church, VA 22041-3258

HQDA ATTN: DAEN-RDM 20 Massachusetts, NW Washington, D.C. 20314